Check 35,000+ stocks against 26 valuation models and 37 quality factors
Data-driven stock valuation
Which stocks are undervalued right now? Check free
Discover now →
Safilo Group (0NJ5) fair value: what the stock is really worth
As of Oct 2, 2026: fair value of Safilo Group €3.02, price €1.80, upside +67.4%, quality 71 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
- Fair value above price? Yes
- Good quality? Yes
- Add to watchlist
SG
Some data
Sep 24, 2026
Safilo Group
0NJ5 · LSEClearly undervaluedStrong Fair Value upside, but quality is only moderate.
✓Fair value €3.02 · Strongly undervalued (+67.4%)
✓Quality 71/100
!Weak Growth (revenue 5y +4.7 %/yr)
!Thin margins · 5.0% net margin (TTM)
✓Moderate debt · generates free cash flow
!Narrow moat 41/100
!Evidence only medium, so the estimate is less certain
Watch Safilo Group for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.
Watch for free
Pro now: $1 first month
What runs behind every stock
26
valuation models
8 families, DCF to NCAV
37
quality factors
margins, balance sheet, cashflow, debt
6
AI factors
moat, what no ratio measures
2,000+
data points
verified, per stock, median
69 individual criteria per stock, every one traceable See the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 24, 2026.
How to read this chart
60‑month range €0.4958 – €3.92 · fair‑value band €2.14 – €4.64 · the €1.80 price screens below the €3.02 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Sep 24, 2026.
Company profile
Safilo Group S.p.A., together with its subsidiaries, designs, manufactures, and distributes optical frames, sunglasses, sports eyewear, goggles, and helmets in North America, Europe, the Asia Pacific, and internationally.
Show more
Safilo Group S.p.A., together with its subsidiaries, designs, manufactures, and distributes optical frames, sunglasses, sports eyewear, goggles, and helmets in North America, Europe, the Asia Pacific, and internationally. The company offers fashion items under the Boss, Carolina Herrera, Dsquared2, Etro, Isabel Marant, Missoni, Moschino, PORTS, and Victoria Beckham brand names; lifestyle products under the Carrera, Eyewear by David Beckham, Marc Jacobs, Levi's, Tommy Hilfiger, Tommy Jeans, Kate Spade New York, Kurt Geiger, Fossil, HUGO, Juicy Couture, Liz Claiborne, Love Moschino, Pierre Cardin, and Stuart Weitzman brand names; sports and outdoor items under the Smith and Under Armour brand names; and mass cool products under the Blenders, Polaroid, Privé Revaux, and Seventh Street brand names. It sells its products to opticians, optometrists, ophthalmologists, retail chains, department stores, specialty retailers, boutiques, duty free, and sports stores through a network of independent distribution partners, direct-to-consumer e-commerce platforms, and online sales channels. The company was formerly known as Società Azionaria Fabbrica Italiana Lavorazione Occhiali S.p.A. and changed its name to Safilo Group S.p.A. in June 2007. Safilo Group S.p.A. was founded in 1878 and is headquartered in Padua, Italy.
Stock analysis
Safilo Group (0NJ5) currently trades at €1.80, while our model-based Fair Value estimate is €3.02, implying the stock looks roughly 40.3% undervalued today.
Show more
Valuation
Bull case: the Multiples group reads highest at a median of €3.72 per share, and 18 of the 22 models we run sit above the €1.80 price.
Bear case: the Earnings-Based group reads lowest at €1.18, and 4 of the 22 models stay below the price. Evidence for this calculation is medium.
Scenario range: €2.14 (bear) to €4.64 (bull), the price of €1.80 sits below it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 71/100 (solid quality), in the Healthcare sector.
Weak Growth: Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.
Safilo Group reported revenue of €983M in FY2025 versus €970M in FY2021, a compound +0.4%/yr. Reported net income was €48.6M in FY2025, compounding +23.0%/yr from FY2021.
Key figures
Market cap €364M · P/E ratio 0.2 · EPS (TTM) €0.0700 · Dividend yield 0.1% · Net margin 4.9% · Return on equity 11.6% · Return on assets (EBIT) 5.7% · Operating margin 2.4%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 50 out of 100 (low confidence).
What moves the price
The share trades about 19% below its 52-week high and 20% above its 52-week low, currently above its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −37% fair-value upside, at 67%, 0NJ5 screens cheaper than that median.
Fair Value models
Bear €2.14
Fair Value €3.02
Bull €4.64
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Based on fiscal year 2025 figures (about 9 months old). Earnings retained since then (€0.0529 per share) are deliberately not added.
Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.
Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Highest evidence
FCF DCF
€2.32
€3.29
€4.91
80
Growth DCF
€2.42
€3.34
€4.76
79
Owner Earnings
€2.20
€3.13
€4.69
76
All 22 models by family
DCF Models
FCF DCF
€2.32
€3.29
€4.91
80
Owner Earnings
€2.20
€3.13
€4.69
76
5Y Revenue Exit
€1.98
€3.13
€4.81
72
5Y EBITDA Exit
€2.95
€4.81
€7.27
74
5Y P/E Exit
€2.27
€3.63
€5.26
70
10Y Revenue Exit
€2.05
€2.86
€3.72
68
10Y EBITDA Exit
€2.65
€3.81
€5.04
69
10Y P/E Exit
€2.27
€3.14
€3.96
65
Earnings-Based
Graham-Dodd
€1.49
€1.82
€2.05
67
EPV
€0.9300
€1.18
€1.38
74
Multiples
P/E Multiple
€3.61
€4.82
€6.02
63
P/S Multiple
€2.79
€3.72
€4.65
58
P/B Multiple
€2.79
€3.72
€4.65
55
EV/EBIT
€3.08
€4.39
€5.71
65
EV/EBITDA
€4.16
€5.84
€7.51
67
EV/Revenue
€1.95
€3.16
€4.36
53
Asset-Based
NCAV (Graham)
€0.8800
€1.18
€1.77
54
Growth DCF
Growth DCF
€2.42
€3.34
€4.76
79
Rev-Margin DCF
€1.98
€3.22
€4.75
72
Economic Profit
Residual Income
€1.57
€1.76
€2.09
76
ROIC Compounder
€0.9300
€1.18
€1.38
72
Growth Earnings
Growth-Adj P/E
€2.55
€3.64
€4.73
67
Notify me when 0NJ5 reaches fair value
Put 0NJ5 on your watchlist. We get in touch as soon as price and fair value meet or the trend turns.
Set up alert →Quality Score breakdown
Overall quality
71/100
Of which business quality 69 · Market factors (momentum, volatility) 46
Profitability
66
Margins and returns on capital today
Quality Growth
70
Are margins and returns improving?
Cashflow
67
Earnings quality: real cash, not paper profit
Fin. Strength
53
Balance sheet, leverage, solvency risk
Investment
100
Disciplined investing over empire-building
Low Volatility
45
Calm price path (market factor)
Momentum
49
Price trend over the last 3–12 months (market factor)
52W Momentum
42
Distance to the 52-week high (market factor)
Net Issuance
75
Share count: buybacks or dilution?
Revenue & earnings trend
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.
40/100
Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.
Revenue growth 1 year
−1.0%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−3.0%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+4.7%
Start year 2020 (pandemic). Over 10 years: −2.6% a year
Revenue growth 21 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+0.2%
’14
’15
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
What shareholders gained per year (last 5 years) ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate.
+10.6%
Earnings growth per share plus dividend.
Earnings per share, growth per year+10.5%
Dividend (yield on the price)0.1%
Pace: 5 vs 10 years ⓘTwo data points, not a trend model: earnings growth per share over the last 5 fiscal years against the last 10. Labelled "steady" when both rates are within 3 percentage points of each other, otherwise picking up or flattening. Shown only when ten years of history exist.10.5% vs −15.5%, picking up
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.−8% → 7%
Start year 2020 (pandemic)
⚠ Revenue per share shrinking 18.6%/yr over ~10Y (margins eroding too) ⓘStructural-decline marker: revenue PER SHARE has fallen over the last decade (robust median trend, not a single year). Backtested across 2005 to 2017, such businesses trailed the market by about 2.5 percentage points per year. Display only: it does not change the fair value or the quality score.
Growth Forecast
Price in line with expectations
The price assumes about as much growth as the company has delivered so far and about what analysts expect.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+4.1%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect ⓘAnalysts publish sales forecasts for the next two fiscal years. For the years after that, growth slows evenly to 2 % a year by year ten (2 % is the long-run rate our models use). Projected years are marked as such.
+3.0%
Yearly sales growth analysts expect, extended to five years.
After inflation (euro area: IMF forecast 2.2% a year to 2030, 2.6% from 2016 to 2025) that is about +1.9% a year for the price and +0.8% for the forecasts.
Forecast 2026 (sales)−0.5%
Forecast 2027 (sales)+4.4%
Projected 2028 (sales)+4.1%
Projected 2029 (sales)+3.8%
Projected 2030 (sales)+3.5%
Watch 0NJ5, get fair value alerts →
Compare Safilo Group with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Instruments & Supplies · 185 stocks
Beats the industry median on 6/11 measures
A mixed picture versus its industry peers.
Valuation Multiplesvs Medical Instruments & Supplies median · lower = cheaper
Context: sector, industry, market
- Is the Health Care sector expensive or cheap?
- P/E, EV/EBITDA and margins by industry (reference tables)
- Undervalued stocks: UK Stocks
- Valuation of the UK market
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
None of the checked exposures detected
Similar stocks
10 more Medical Instruments & Supplies stocks, each showing price versus our Fair Value estimate.
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Intuitive Surgical, Inc ISRG | $406.63 | $348.72 | −14% |
| EssilorLuxottica Société anonyme EL | €144.60 | €159.06 | +10% |
| Becton, Dickinson and Company BDX | $178.07 | $104.73 | −41% |
| Medline Inc MDLN | $34.70 | $29.06 | −16% |
| Alcon Inc ALC | $63.94 | $40.13 | −37% |
| West Pharmaceutical Services, Inc WST | $375.65 | $137.81 | −63% |
| Sartorius Stedim Biotech S.A DIM | €208.20 | €54.82 | −74% |
| Straumann Holding STMN | CHF 89.80 | CHF 45.50 | −49% |
| Sartorius Aktiengesellschaft SRT | €206.50 | €42.05 | −80% |
| Solventum Corporation SOLV | $89.50 | $134.36 | +50% |
Explore undervalued stocks
More undervalued Healthcare stocks →
All undervalued stocks
TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend Stocks
Try a ready-made strategy
Pick a strategy and jump into the live analysis with that exact screen applied.
🥇 Backtested Best
🏆 Big Names
⭐ Top Rated
💎 Quality on Sale
🚀 Profitable Growth
🧊 Quality Compounders
💵 Dividend Stars
📈 Strong Momentum
📉 Fallen Angels
⚖️ Deeply Undervalued
🔍 Small-Cap Gems
🏰 Moat at a Fair Price
💼 Insider Buying
🎩 Buffett-Style Quality
📚 Peter Lynch GARP
🧮 Greenblatt Magic Formula
🛡️ Graham Defensive
Discover tools
Stock screenerFilter by region, size and sector
Compare toolTwo stocks side by side
Extrinsic Value Calculator…Calculator with industry benchmark
Peter Lynch Fair Value Formula &…Calculator with industry benchmark
Run the numbers yourself: free valuation calculators
Frequently asked questions
Is Safilo Group (0NJ5) overvalued or undervalued?
As of Sep 24, 2026, our model estimates a fair value of €3.02 versus a price of €1.80, about +67% upside (undervalued).
What is the fair value of 0NJ5?
Our model-based fair value for Safilo Group is €3.02 (as of Sep 24, 2026), built from audited fundamentals. The current price: €1.80.
What is the quality score of 0NJ5?
Safilo Group has a Quality Score of 71/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Safilo Group (0NJ5)?
Our model-based price target is the fair value of €3.02 (as of Sep 24, 2026) from 22 valuation models. Cautious scenario €2.14, optimistic scenario €4.64. It is a calculation from audited fundamentals, not an analyst target.
What is the Safilo Group stock forecast for 2026?
Our models put fair value at €3.02, about +67% upside versus a price of €1.80 (undervalued). Cautious scenario €2.14, optimistic scenario €4.64. The calculation is refreshed regularly with new filings.
What is the revenue of Safilo Group (0NJ5)?
Safilo Group reported trailing-twelve-month revenue of about €983M (latest available figure, as of Sep 24, 2026).
Does Safilo Group pay a dividend?
Safilo Group currently shows a dividend yield of about 0.08% relative to its recent price (as of Sep 24, 2026).
What growth is priced into Safilo Group (0NJ5)?
For today's price to be fair in a discounted-cash-flow model, Safilo Group would have to grow free cash flow by +4.1 % per year for five years (discount rate 11.8 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +4.7 % per year. As of Sep 24, 2026.
What discount rate (WACC) does the fair value of 0NJ5 use?
Our models discount Safilo Group at 11.8 %: a base by market capitalisation (small), damped by beta 1.00, country premium for United Kingdom. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Safilo Group that is +4.1 % per year a year over ten years, using the same discount rate (11.8 %) and the same formula as our fair value.
How much growth has Safilo Group (0NJ5) delivered so far?
Over the past 5 years revenue at Safilo Group grew +4.7 % a year. The price currently implies +4.1 % per year free-cash-flow growth a year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Safilo Group (0NJ5) growing?
The median revenue growth in the sector is +7.0 % a year. That is the yardstick for the growth priced into Safilo Group (+4.1 % per year a year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Safilo Group (0NJ5)?
The free-cash-flow yield on the price is 10.74 %: that much free cash flow Safilo Group produces per unit of market value. When it exceeds the discount rate of our models (11.8 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Safilo Group (0NJ5)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Safilo Group it is €3.02 per share (as of Sep 24, 2026), against a price of €1.80. It is the blended result of 22 valuation models (cash flow, earnings, asset, dividend).
Is Safilo Group stock overvalued or undervalued in 2026?
As of Sep 24, 2026, 0NJ5 trades below its calculated fair value: price €1.80, fair value €3.02, a gap of about +67% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 0NJ5?
No. The price is what the market pays today (€1.80); the fair value is what the company's own numbers justify (€3.02). For Safilo Group the two are €1.22 per share apart. That gap is exactly why we show both numbers side by side.
How much is Safilo Group worth?
The market values Safilo Group at about €364M (market capitalisation, as of Sep 24, 2026). Per share that is €1.80; our models calculate a fair value of €3.02 per share.
What do the bullish and bearish scenarios say about 0NJ5?
Our models span a range for Safilo Group: cautious scenario €2.14, base €3.02, optimistic €4.64 per share (as of Sep 24, 2026, price €1.80). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of 0NJ5?
Safilo Group trades at a price-to-earnings ratio of 0.2 (as of Sep 24, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of €3.02 is built from several models across several years.
How solid is the balance sheet of Safilo Group (0NJ5)?
Balance-sheet figures for Safilo Group (as of Sep 24, 2026): return on equity 11.6%, debt of 0.62 per unit of equity. They feed the Quality Score of 71/100, which measures business quality independently of the share price.
How far is 0NJ5 from its 52-week high?
Safilo Group trades at €1.80, about 19% below its 52-week high of €2.24 and 20% above the low of €1.51 (as of Oct 2, 2026). Distance from the high says nothing about value: that is what the fair value of €3.02 is for.
Which stocks are comparable to Safilo Group?
From the same area (Healthcare) we also value Intuitive Surgical, Inc, EssilorLuxottica Société anonyme, Becton, Dickinson and Company, Medline Inc, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Safilo Group stock attractive at the current price?
The data as of Sep 24, 2026: price €1.80, calculated fair value €3.02 (+67%), Quality Score 71/100, from 22 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 0NJ5 calculated?
We run Safilo Group through 22 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of €3.02, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.5 % above its aggregate fair value. Safilo Group currently trades 40 % below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Safilo Group (0NJ5)?
The closing price on Oct 2, 2026 was €1.80. Our model-based fair value is €3.02, about +67% upside (undervalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Safilo Group right now?
The rarer combination: high quality (71/100) AND below fair value. That earns a closer look rather than a quick verdict. The price is below even our cautious bear case (€2.14). The market is more pessimistic than our downside scenario. A fairly wide model range (€2.14 to €4.64) leaves room in how you read the outcome.
Key figures of Safilo Group
How large is the market capitalisation of Safilo Group (0NJ5)?
The market capitalisation of Safilo Group is €364M. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What are the earnings per share of Safilo Group (0NJ5)?
Earnings per share at Safilo Group are €0.0700 (price ÷ EPS = P/E 0.2). Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of Safilo Group (0NJ5)?
The dividend yield of Safilo Group is 0.1% (payout 2.0%). Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Safilo Group (0NJ5)?
The net margin of Safilo Group is 4.9% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Safilo Group (0NJ5)?
The return on equity (ROE) of Safilo Group is 11.6% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Safilo Group (0NJ5)?
On an EBIT basis the return on assets of Safilo Group is 5.7% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Safilo Group (0NJ5)?
The operating margin of Safilo Group is 2.4% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Safilo Group (0NJ5)?
Revenue at Safilo Group is growing −3.4% versus a year earlier (3y avg −3.0%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Safilo Group (0NJ5)?
Earnings per share at Safilo Group are growing +47.6% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net debt does Safilo Group (0NJ5) carry?
The net debt of Safilo Group is €46.1M (fiscal year 2025, ≈ 0.6 yrs of FCF). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch Safilo Group in the live analysis
One click puts Safilo Group on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
Watch for free →Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.